Assay News and Research

RSS

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Light-switching complex could help detect signs of Alzheimer's disease

A breakthrough in sensing at Rice University could make finding signs of Alzheimer's disease nearly as simple as switching on a light.

14 Jul 2011

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.

14 Jul 2011

Illumina announces availability of new TruSeq Custom Enrichment kits

Illumina, Inc. today announced availability of its new TruSeq Custom Enrichment kits which enable researchers to economically design and target genomic regions of interest ranging from 700 kilobases (Kb) to 15 megabases (Mb) of cumulative DNA.

From Illumina, Inc. 13 Jul 2011

Indirubin might help treat glioblastoma

The active ingredient in a traditional Chinese herbal remedy might help treat deadly brain tumors, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

13 Jul 2011

Rapid method can predict immune responses against flu vaccines

Researchers at the Emory Vaccine Center have developed a method for predicting whether someone will produce high levels of antibodies against a flu shot a few days after vaccination.

12 Jul 2011

New animal model for studying development of testicular germ cell tumors

A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.

12 Jul 2011

Affymetrix commences shipment of gene profiling reagents

Affymetrix, Inc. today began shipping its FDA-cleared Gene Profiling Reagents. Affymetrix also announced the availability of the new Gene Profiling Array cGMP U133 P2, a version of the widely cited Human Genome U133 Plus 2.0 Array, as another component to its GeneChip Instrument System, which is used by Affymetrix partners for assay development.

12 Jul 2011

New genetic research on Ankylosing Spondylitis

The team of researchers from the Universities of Bristol, Queensland, Oxford, Texas and Toronto, used a technique called genome-wide association where millions of genetic markers are measured in thousands of people that have the disease and thousands of healthy individuals.

11 Jul 2011

Two defective genes may cause telomere elongations in cancer cells: Study

Scientists at Johns Hopkins have provided more clues to one of the least understood phenomena in some cancers: why the "ends caps" of cellular DNA, called telomeres, lengthen instead of shorten.

1 Jul 2011

Roche introduces new real-time PCR system

With "Size: Reduced. Fun: Amplified.", Roche Applied Science launched its new real-time PCR system on June 27th, 2011. The small, silent, sleek LightCycler Nano Instrument supports state-of-the-art technology for fast PCR protocols featuring leading edge thermal resolution and reproducibility.

1 Jul 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.

28 Jun 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Polymedco, Inc. is pleased to announce the direct availability of the BTA stat® test from our sales force – The BTA stat® test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine.

27 Jun 2011

McMaster researchers to use tiny worms for Parkinson's project

McMaster researchers from three disciplines are deploying thousands of tiny worms and a homegrown invention to test drugs in a collaborative bid to defeat Parkinson's Disease.

27 Jun 2011

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify potential therapeutic agents against its novel disease-based targets, or its partners' targets, announced today that it opened its new medicinal chemistry space at 8 Black Forest Road in Hamilton, NJ.

22 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

Free ADAP 2.0 software upgrade with Biochrom's EZ Read 400 research reader

Busy laboratory environments require a microplate reader with the flexibility to cover many assay types, and software that delivers fast, reliable analysis. With this in mind, Biochrom are offering a free software upgrade from ADAP 2.0 Basic to ADAP 2.0 Plus with purchases of the EZ Read 400 research reader until 30 September 2011. For further information, visit www.biochrom.co.uk.

From Biochrom Ltd. 20 Jun 2011

Randox launches automated laboratory assay for Heart-type Fatty Acid Binding Protein

Randox Laboratories, the international clinical diagnostics company, has today launched an automated laboratory assay for Heart-type Fatty Acid Binding Protein (H-FABP), to improve the diagnosis and management of patients with suspected acute coronary syndrome (ACS).

From Randox Laboratories Ltd. 20 Jun 2011